tetano
Editor, Senior Moderator
Isr Med Assoc J
. 2022 Jan;24(1):9-10.
Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Giuliana Galassi[SUP] 1 [/SUP], Vittorio Rispoli[SUP] 1 [/SUP], Erika Iori[SUP] 1 [/SUP], Alessandra Ariatti[SUP] 1 [/SUP], Alessandro Marchioni[SUP] 2 [/SUP]
Affiliations
Abstract
The Oxford-AstraZeneca vaccine ChAdOx1 (AZD1222, Vaxzevria) is playing a crucial role in counteracting the coronavirus disease-2019 (COVID-19) pandemic [1]. Since March 2021, reports of unexpected thrombotic events associated with thrombocytopenia and vaccination have been published [2]. To the best of our knowledge there is only one report about vaccination-associated myasthenia gravis (MG) occurring after a second dose of BNT162b2 (Pfizer-BioNTech).
. 2022 Jan;24(1):9-10.
Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Giuliana Galassi[SUP] 1 [/SUP], Vittorio Rispoli[SUP] 1 [/SUP], Erika Iori[SUP] 1 [/SUP], Alessandra Ariatti[SUP] 1 [/SUP], Alessandro Marchioni[SUP] 2 [/SUP]
Affiliations
- PMID: 35077038
Abstract
The Oxford-AstraZeneca vaccine ChAdOx1 (AZD1222, Vaxzevria) is playing a crucial role in counteracting the coronavirus disease-2019 (COVID-19) pandemic [1]. Since March 2021, reports of unexpected thrombotic events associated with thrombocytopenia and vaccination have been published [2]. To the best of our knowledge there is only one report about vaccination-associated myasthenia gravis (MG) occurring after a second dose of BNT162b2 (Pfizer-BioNTech).